CLOTRIMAZOLE EXTRA STRENGTH EXTERNAL ANTIFUNGAL CREAM

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

CLOTRIMAZOLE

Tilgjengelig fra:

TARO PHARMACEUTICALS INC

ATC-kode:

G01AF02

INN (International Name):

CLOTRIMAZOLE

Dosering :

2%

Legemiddelform:

CREAM

Sammensetning:

CLOTRIMAZOLE 2%

Administreringsrute:

VAGINAL

Enheter i pakken:

15G/50G

Resept typen:

OTC

Terapeutisk område:

AZOLES

Produkt oppsummering:

Active ingredient group (AIG) number: 0110231003; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2020-08-18

Preparatomtale

_ _
_CLOTRIMAZOLE VAGINAL 6 _
_CLOTRIMAZOLE VAGINAL 3 _
_CLOTRIMAZOLE EXTERNAL CREAM _
_CLOTRIMAZOLE EXTERNAL ANTIFUNGAL CREAM _
_CLOTRIMAZOLE EXTRA STRENGTH EXTERNAL ANTIFUNGAL CREAM _
_ PAGE 1 OF 29 _
PRODUCT MONOGRAPH
CLOTRIMAZOLE VAGINAL 6
(Clotrimazole Vaginal Cream USP 1%)
CLOTRIMAZOLE VAGINAL 3
(Clotrimazole Vaginal Cream USP 2%)
CLOTRIMAZOLE EXTERNAL CREAM
(Clotrimazole
Cream USP 1%) CLOTRIMAZOLE EXTERNAL ANTIFUNGAL CREAM
(Clotrimazole
Cream USP 1%)
CLOTRIMAZOLE EXTRA STRENGTH EXTERNAL ANTIFUNGAL
CREAM
(Clotrimazole
Cream USP 2%)
ANTIFUNGAL AGENT
Taro Pharmaceuticals
Inc.
Date of Revision:
130 East Drive
April 29, 2022
Brampton, Ontario
L6T 1C1
Control # 263251
_ _
_CLOTRIMAZOLE VAGINAL 6 _
_CLOTRIMAZOLE VAGINAL 3 _
_CLOTRIMAZOLE EXTERNAL CREAM _
_CLOTRIMAZOLE EXTERNAL ANTIFUNGAL CREAM _
_CLOTRIMAZOLE EXTRA STRENGTH EXTERNAL ANTIFUNGAL CREAM _
_ PAGE 2 OF 29 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................
3
SUMMARY
PRODUCT
INFORMATION
............................................................................................
3
INDICATIONS
AND
CLINICAL
USE..................................................................................................
3
CONTRAINDICATIONS
.....................................................................................................................
4
WARNINGS
AND
PRECAUTIONS
.....................................................................................................
4
ADVERSE
REACTIONS
.....................................................................................................................
5
DRUG
INTERACTIONS
......................................................................................................................
6
DOSAGE
AND
ADMINISTRATION
...................................................................................................
6
OVERDOSAGE
...................................................................................................